StockDuty ← Dashboard Nov 12, 2026 03:55 PM ET
SignalEarnings

$MRNA (Moderna) — 8-K: MRNA Q3 FY26: EPS $0.38 vs $-1.25 consensus — a +130.3% beat; FY26 revenue growth guide raised to 15%-25%

MRNA
$223.37
-3.45%
Moderna posted Q3 FY26 GAAP diluted EPS of $0.38, crushing the $-1.25 consensus by $1.63 (+130.3%), with net income of $162M versus a $(200)M loss a year ago. Total revenue came in at $1,313M, up 29.2% YoY, and management raised its FY2026 revenue growth outlook to 15%-25% from up to 10%, while lifting its year-end cash guide to $8.1B-$8.3B. The top-line beat was driven by higher COVID vaccine sales in international markets, supported by deliveries under long-term strategic government partnerships.
Moderna posted Q3 FY26 GAAP diluted EPS of $0.38, crushing the $-1.25 consensus by $1.63 (+130.3%), with net income of $162M versus a $(200)M loss a year ago. Total revenue came in at $1,313M, up 29.2
Sources